Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape

Glioblastoma multiforme (GBM) is among the most difficult cancers to treat with a 5-year survival rate less than 5%. An immunotherapeutic vaccine approach targeting GBM-specific antigen, EGFRvIII, previously demonstrated important clinical impact. However, immune escape variants were reported in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Daniel H., Liaw, Kevin, Bhojnagarwala, Pratik, Zhu, Xizhou, Choi, Jihae, Ali, Ali R., Bordoloi, Devivasha, Gary, Ebony N., O’Connell, Ryan P., Kulkarni, Abhijeet, Guimet, Diana, Smith, Trevor, Perales-Puchalt, Alfredo, Patel, Ami, Weiner, David B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006507/
https://www.ncbi.nlm.nih.gov/pubmed/36915911
http://dx.doi.org/10.1016/j.omto.2023.02.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006507/
https://www.ncbi.nlm.nih.gov/pubmed/36915911
http://dx.doi.org/10.1016/j.omto.2023.02.004

Ejemplares similares